Healthcare
Embecta Corp.(EMBC)
Live Price
Offline$3.11
+0.65% today
1Y Change
-68.68%
Window
Jun 25, 2025 → Jun 18, 2026
- Market Cap
- $230.00M
- Revenue Growth
- -3.8%
- EPS Growth
- +20.6%
- Dividend Yield
- 15.4%
Coverage: 247 bars · Jun 25, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Embecta Corp. (EMBC) is a Healthcare stock with a market cap of $230.00M and listed on NASDAQ. The stock last traded around $3.11 and down 68.7% across the available one-year price window (Jun 25, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -3.8%, EPS growth of +20.6%, a dividend yield of 15.4%. What stands out right now is revenue -3.8%, EPS +20.6%, free cash flow +816.6% with operating margin 27.7% and ROIC 24.0%. The dividend matters to the case here, with a current yield around 15.4%. Valuation is more restrained than many high-expectation growth names at P/E 2.0 and price/sales 0.2. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines EMBC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.8% vs +7.6% peer median
Operating Margin
Above sector median
+27.7% vs +19.4% peer median
P/E
Below sector median
2.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -3.8% and EPS is at +20.6%, with operating margin around 27.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 15.4%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
EMBC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EMBC
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EMBC Max Drawdown
-81.06%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EMBC and SPY.
Company Overview
Embecta Corp.
NASDAQ Global Select
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
- Leadership
- Devdatt Kurdikar
- IPO Date
- Mar 22, 2022
- Employees
- 2.0k
- Street Address
- 300 Kimball Drive
- Mailing
- Parsippany, NJ, 07054
- Region
- Parsippany, NJ, US
- Reporting Currency
- USD
- Investor Line
- 201 847 6880
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 2.0
- EV/EBITDA
- 4.5
- Price/Sales
- 0.2
- Price/Book
- —
Growth
- Revenue
- -3.8%
- EPS
- +20.6%
- Free Cash Flow
- +816.6%
Profitability
- Gross Margin
- 61.4%
- Operating Margin
- 27.7%
- Net Margin
- 10.7%
- ROE
- -17.5%
- ROIC
- 24.0%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 2.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.